Výsledky vyhledávání

Dissertation/ Thesis

Ideology and Class Conflicts in _Sons and Lovers

88
This thesis is an attempt to understand the ideologies of _Sons and Lovers_ through the class conflicts in content and form and the influence of Lawrence''s life experience and the ideology of organicism on his views of life force. _Sons and

Externí odkaz: http://ndltd.ncl.edu.tw/handle/26153798650231644285

Zobrazit plný text záznamu

Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia Α

Autor: Adam Giermasz, Nathan Visweshwar, Thomas J. Harrington, Andrew D Leavitt, Barbara Konkle, Jeremy Rupon, Gregory Di Russo, Li-Jung Tseng, Maria de los Angeles Resa, Florence Ganne, Delphine Agathon, Frank Plonski, Didier Rouy, Bettina M. Cockroft, Annie Fang, Steven Arkin

Publikováno v: Blood. 140:7776-7777

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4584da51b0298fa0ee57dc5c01df65a7
https://doi.org/10.1182/blood-2022-159421

Zobrazit plný text záznamu

Effect of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intravenous Rivipansel

Autor: David Robert John Readett, Anna Plotka, Hua Wei, Kelly A. Ryan, Brinda Tammara, Annie Fang, Joan M. Korth-Bradley, Frank E. Shafer

Publikováno v: Clinical pharmacology in drug developmentReferences. 9(8)

Two studies evaluated the effects of renal and hepatic impairment on pharmacokinetics and safety of rivipansel (NCT02813798, NCT02871570). A single intravenous 840-mg rivipansel dose was administered to subjects with renal impairment or normal renal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1081ca5f000b278dee583089fbd8e1f
https://pubmed.ncbi.nlm.nih.gov/32579796

Zobrazit plný text záznamu

First prospective comparison of genotypic versus phenotypic tropism assays in predicting virologic responses to maraviroc in a phase 3 study

Autor: Jayvant, Heera, Srinivas R, Valluri, Charles, Craig, Annie, Fang, Neal, Thomas, Ralph D, Meyer, Marilyn E, Lewis, Elna, van der Ryst, James, Demarest

Publikováno v: The new microbiologica. 42(2)

Maraviroc (MVC, a CCR5 antagonist) is only fully active against CCR5 tropic [R5] HIV-1, and tropism testing is required prior to initiating treatment. The MODERN study prospectively compared genotypic (GTT) and phenotypic (Trofile®) tropism testing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d6fdace2c3dc7f3ba5943c46e92f2a48
https://pubmed.ncbi.nlm.nih.gov/31034084

Zobrazit plný text záznamu

Updated Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (SB-525) Gene Therapy in Adults with Severe Hemophilia a

Autor: Nathan Visweshwar, Jeremy Rupon, Annie Fang, Frank Plonski, Lynne Smith, Adam Giermasz, Steven Arkin, Gregory Di Russo, Kimo C. Stine, Li-Jung Tseng, Andrew D. Leavitt, Didier Rouy, Barbara A. Konkle, Bettina M. Cockroft, Thomas J. Harrington

Publikováno v: Blood. 136:12-12

Introduction: Hemophilia A is a rare bleeding disorder caused by pathogenic variants in the F8 gene, resulting in insufficient factor VIII (FVIII) activity. Adeno-associated virus (AAV)-mediated gene transfer enables the delivery of a modified functi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f4f055c187dbd8a7089c6e1906c19d5c
https://doi.org/10.1182/blood-2020-137648

Zobrazit plný text záznamu

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects

Autor: Sunil Nepal, Mark E. Savage, Kimberly Y. Smith, Manoli Vourvahis, Phylinda L. S. Chan, Srinivas Rao Valluri, Julian J Haynes, Lynn McFadyen, Jayvant Heera, Andrew Clark, Linda S. Wood, Annie Fang, Gwendolyn D. Fate, Angus N. R. Nedderman, Jean-Claude Marshall

Publikováno v: Journal of Clinical Pharmacology

Maraviroc is a C‐C chemokine receptor type‐5 antagonist approved for the treatment of HIV‐1. Previous studies show that cytochrome P450 3A5 (CYP3A5) plays a role in maraviroc metabolism. CYP3A5 is subject to a genetic polymorphism. The presence

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::163186c5f22a0287699d825327c2ada7
https://pubmed.ncbi.nlm.nih.gov/30192390

Zobrazit plný text záznamu

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1

Autor: Marinella Della Negra, Srinivas Rao Valluri, Carlo Giaquinto, Kulkanya Chokephaibulkit, Manoli Vourvahis, Ismail Mitha, Andrew Clark, Jan Fourie, Jayvant Heera, Charles Craig, Rebecca Yanhui Zhang-Roper, Lynn McFadyen, Elna van der Ryst, Muthuhadini Patience Mawela, Annie Fang

Publikováno v: The Pediatric Infectious Disease Journal

Supplemental Digital Content is available in the text.
Background: Maraviroc is a CC-chemokine receptor 5 antagonist approved to treat adults infected with CC-chemokine receptor 5–tropic (R5) HIV-1. Study A4001031 was conducted to evaluate the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f80069e97e7c0f7c3305dba6fd350d3
https://pubmed.ncbi.nlm.nih.gov/29023357

Zobrazit plný text záznamu

Pharmacokinetic Interaction between Maraviroc and Fosamprenavir-Ritonavir: an Open-Label, Fixed-Sequence Study in Healthy Subjects

Autor: Anna Plotka, Annie Fang, Jayvant Heera, Manoli Vourvahis, Laure Mendes da Costa

Publikováno v: Antimicrobial Agents and Chemotherapy. 57:6158-6164

This open-label, fixed-sequence, phase 1 study evaluated the pharmacokinetic interaction between maraviroc (MVC) and ritonavir-boosted fosamprenavir (FPV/r) in healthy subjects. In period 1, subjects received 300 mg of MVC twice daily (BID; cohort 1)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ea1b14f05c5aec41ca118a9a99e0bdb
https://doi.org/10.1128/aac.01098-13

Zobrazit plný text záznamu

Effect of Renal Impairment on the Pharmacokinetics and Safety of Rivipansel in Subjects with Renal Impairment and in Healthy Subjects

Autor: Annie Fang, David Robert John Readett, Joan M. Korth-Bradley, Hua Wei, Brinda Tammara, Kelly A. Ryan, Frank E. Shafer, Anna Plotka

Publikováno v: Blood. 132:1083-1083

Background: Rivipansel is a pan-selectin inhibitor in phase 3 development for treatment of sickle cell disease vaso-occlusive crises. Previous studies have shown almost complete elimination of unchanged drug in urine following an intravenous (IV) inf

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1a17cf7bbaeaabd7fc9581ca3e15e0d3
https://doi.org/10.1182/blood-2018-99-111926

Zobrazit plný text záznamu

Comparative Pharmacokinetics of Voriconazole Administered Orally as either Crushed or Whole Tablets

Autor: Annie Fang, John R. Perfect, Aimee K. Zaas, E. S. Dodds Ashley, Bharat Damle

Publikováno v: Antimicrobial Agents and Chemotherapy. 51:877-880

Voriconazole is a triazole antifungal agent used to treat serious, invasive fungal infections including aspergillosis and candidemia. Limitations with existing formulations of voriconazole including restricted utility in patients with renal dysfuncti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d9e6b13e25f304ffcd63a7481063b17
https://doi.org/10.1128/aac.01263-06

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání